General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-02 | 2024-03 | -0.18 | -0.2 | -0.02 | -11.11% |
2024-03-11 | 2023-12 | -0.23 | -0.2 | 0.03 | 13.04% |
2023-11-08 | 2023-09 | -0.22 | -0.21 | 0.01 | 4.55% |
2023-08-03 | 2023-06 | -0.17 | -0.22 | -0.05 | -29.41% |
2023-05-02 | 2023-03 | -0.17 | -0.17 | N/A | N/A |
2023-03-02 | 2022-12 | -0.14 | -0.16 | -0.02 | -14.29% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-05-30 | Citigroup | Upgrade | Buy | Buy |
2023-05-29 | Needham | Upgrade | Hold | |
2023-03-06 | Jefferies | Upgrade | Hold | |
2022-11-21 | Citigroup | Upgrade | Buy | Buy |
2022-08-11 | Piper Sandler | Upgrade | Overweight | |
2022-06-30 | Citigroup | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-04-25 | AMOUYAL PHILIPPE J | Director | 248.36K | Conversion of Exercise of derivative security |
2024-05-09 | ARTAL INTERNATIONAL S.C.A. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
2024-04-25 | BARKER SAMUEL L | Director | 87.65K | Conversion of Exercise of derivative security |
2024-02-27 | COATS LONNEL | Chief Executive Officer | 1.10M | Conversion of Exercise of derivative security |
2024-04-25 | DEBBANE RAYMOND | Director | 6.80M | Conversion of Exercise of derivative security |
2024-04-25 | LEFKOWITZ ROBERT J | Director | 48.36K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Artal Group S.A. | 117.55M | 269.20M | 48.00% |
2023-06-29 | BVF Inc. | 20.00M | 45.79M | 8.16% |
2023-06-29 | FMR, LLC | 8.51M | 19.49M | 3.47% |
2023-06-29 | Vanguard Group Inc | 6.46M | 14.79M | 2.64% |
2023-06-29 | Blackrock Inc. | 6.38M | 14.61M | 2.60% |
2023-06-29 | JP Morgan Chase & Company | 2.93M | 6.71M | 1.20% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.70M | 8.48M | 1.51% |
2023-08-30 | Fidelity Growth Company Fund | 2.53M | 4.35M | 1.03% |
2023-08-30 | iShares Russell 2000 ETF | 2.15M | 3.69M | 0.88% |
2023-06-29 | JP Morgan Small Cap Value Fund | 1.43M | 3.27M | 0.58% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.42M | 3.25M | 0.58% |
2023-08-30 | Fidelity Select Portfolios - Biotechnology | 1.09M | 1.87M | 0.44% |
Split | Date |
---|---|
1 : 7 | 2015-05-21 |
IMO no way Coats decided on his own to retire and that’s ok.
He was the guy to advance Impefa to approval, but they should have replaced him before launching . He is not a sales launch guy.
If we see another impressive hire away from Bristol ( and big pharma really) to take the CEO position , that would be idea and very telling of our success from here.
Next week will be huge, or not. Let’s see.
4 big questions need to be answered.
We need a new CEO, sales infection / new coverage , T1 submission ETA and HCM P3 ETA
I have heard that insurance companies make decisions on coverage mainly around Jan and June 1st. That would make this Friday and early next week a very important time period.
Let go Lexie!
Even the #10 CV drug does over 1 b a year.
Pick your spot on the chart but Impefa should easily make this list at some point in the mid term, any pharm company can see this. Easy to see this in the top 5
Put a 9.7x. On that and we are at 10B easy
$1.60 SP is a strong buy, sleep easy , may take some time but we will 10-20x from here!
https://xtalks.com/top-15-cardiovascular-disease-drugs-in-2023-by-2022-sales-data-3717/
Just set a price target and forget about looking at this SP daily, at best look 1x week on Friday.
Without sales to hold SP up , it’s only going to drift down, until we get PR with news that re-enforces a higher SP. This is what short know to be true. That said it’s a huge gamble
A new CEO announcement could send SP up
New coverage as well, both could happen anytime now, weeks or a month out.
Key is they are very well backed/ funded, have a strong COO, very promising pipeline.
If your not invested to see LX9211 move to P3, not sure what then, that is the promise land and definitely not happening for 12-18 months …..
Possible big announcements before next earnings
New CEO
T1 resubmission executed
HCM moving to phase 3
New coverage
All known, but does not seem Lexi has been getting SP advances on news or rumors, just when they actually do something.
All 4 of these should between June and July, hopefully we get reset SP closer to what it should be, well over $1b ….
On the bright side, Lexi is rated a strong buy on Nasdaq.com, with a low target of $4, consensus of $6.33
I think that low number has gone up recently from $2.50 If memory serves me
Honestly I’ll take the low of $4, that will double my money and then I can sell half and let the houses money ride through LX9211 fate, which ultimately I think the most important driver for all .
If we get a new CEO with they same level of experience as we got with Tom, when they announce new coverage ( they said it was coming really soon) the new shorts may regret entering this trade.
Also, when they actually file for T1 and when they actually enter P3 for HCM, I would think the SP would pop?
Seems like at least 4 short term mini catalyst could be on the horizon, could be wrong, but at the end of the day, when we enter P3 with Lx9211, I think this SP is going to be significantly higher than today.
Possible driver of near term SP
CEO announcement very soon would seem very timely given recent $250 m raise ( had to be part over the conversations, no? Coats had his last call and retiring in about 45 days so we should have some overlap with new and old CEO) share holder meeting May 10th, NSM May 13-17, June 1st a key time around new access ( from recent call “ very shortly expecting more coverage”), July 1 mid year point, should have actual T1 submission and actual P3 commencement for HCM. To boot we are sitting at 20 m short with 9 days to cover, I’m not sure sure there is going to be a better reentry point than where we are at now under $2 with all that on the very near term.
Thoughts?
Next catalyst, a new high powered CEO. Could be this week or next. ( or was Coats departure a complete surprise to Lexi and their recent cohort of investors, not likely) With strong financial backing, a solid COO, and amazing pipeline lined up, Lexi is ready to rip again, especially with 20m short and 9 days to cover. Last time we were at 9 days was mid Jan……
May is going to be very interesting,
Lexi has over 20 m short with 9 days to cover.
If your short right now, would you want to hold right now and wait to hear who gets announced as the new CEO?
With backing and a pipeline like they have the new CEO could be someone very creditable and send shares soaring. If I’m short I’d buy back right now, make my profit and wait and see.
I see a bit of a run over the next week or two , could be wrong? Thoughts? Why stay short , ( in May) how much lower would you be waiting for us to go in the short term with the cash and opportunities in front of us?
The market is telling us this company is for sale